Infection of the macrophage cell line NR8383 with Mycobacterium tuberculosis (H37Ra) leads to an increase in oligodeoxynucleotide accumulation.

Mycobacterium tuberculosis infection continues to be a daunting clinical challenge. Although it may well be one of the most studied bacteria in history, several aspects of its pathology remain a mystery. The resurgence of drug-resistant M. tuberculosis strains and with its unusual pathology have promoted a renewed basic and clinical research interest in developing new therapies to combat this pathogen. The primary localization site for M. tuberculosis is within alveolar macrophages. Drug delivery strategies and novel therapeutic agents designed to target alveolar macrophages may lead to efficient destruction of M. tuberculosis. Oligodeoxynucleotides (ODN) are short segments of nucleic acids that can interfere with transcription and translation processes. In this report, a monocyte-macrophage cell line was characterized in regard to ODN transport in the presence or absence of M. tuberculosis infection. The cells accumulated ODN in a time-dependent and concentration-dependent manner, regardless of the presence of serum. After 4 hours of incubation with M. tuberculosis (multiplicity of infection [MOI] 10:1), infected NR8383 cells demonstrated 1.5-7-fold increase in fluorescein isothiocyanate (FITC)-labeled phosphorothioate ODN accumulation as measured by flow cytometry. The increase in uptake was associated only with fluorescent-labeled ODN and not labeled markers of fluid phase endocytosis (e.g., tetramethylrhodamine isothiocyanate [TRITC], FITC-labeled dextran). NR8383 cells activated by phytohemagglutinin (PHA) did not demonstrate a significant increase in the uptake of either FITC-labeled dextran or FITC-labeled ODN. These studies demonstrate that NR8383 cells that have been infected with M. tuberculosis can specifically accumulate ODN, and this route of accumulation may lead to a means of drug targeting to mycobacteria-containing cells.

[1]  I. Tebbett,et al.  Cocaine Suppresses Fetal Immune System , 1998, Pediatric Research.

[2]  J. Ernst,et al.  Macrophage Receptors for Mycobacterium tuberculosis , 1998, Infection and Immunity.

[3]  G. H. Zhang,et al.  Regulation of cytosolic free Ca2+ in cultured rat alveolar macrophages (NR8383) , 1997, Journal of leukocyte biology.

[4]  W. Martin,et al.  Surfactant protein A (SP-A) mediates attachment of Mycobacterium tuberculosis to murine alveolar macrophages. , 1997, American journal of respiratory cell and molecular biology.

[5]  K. Edwards,et al.  SP-A enhances uptake of bacillus Calmette-Guérin by macrophages through a specific SP-A receptor. , 1997, The American journal of physiology.

[6]  J. Pieters,et al.  Isolation and characterization of the mycobacterial phagosome: segregation from the endosomal/lysosomal pathway , 1997, Molecular microbiology.

[7]  J. Loike,et al.  Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein , 1997, Nature Medicine.

[8]  G. Chaudhuri Scavenger receptor-mediated delivery of antisense mini-exon phosphorothioate oligonucleotide to Leishmania-infected macrophages. Selective and efficient elimination of the parasite. , 1997, Biochemical pharmacology.

[9]  J. Keane,et al.  Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis , 1997, Infection and immunity.

[10]  S. Iyer,et al.  Differences in mannose receptor-mediated uptake of lipoarabinomannan from virulent and attenuated strains of Mycobacterium tuberculosis by human macrophages. , 1996, Journal of immunology.

[11]  M. Horwitz,et al.  The Mycobacterium tuberculosis phagosome interacts with early endosomes and is accessible to exogenously administered transferrin , 1996, The Journal of experimental medicine.

[12]  D. Russell,et al.  Mycobacterium avium- and Mycobacterium tuberculosis-containing vacuoles are dynamic, fusion-competent vesicles that are accessible to glycosphingolipids from the host cell plasmalemma. , 1996, Journal of immunology.

[13]  M. Fenton,et al.  Immunopathology of tuberculosis: roles of macrophages and monocytes , 1996, Infection and immunity.

[14]  V. Metelev,et al.  Antimycobacterial activities of antisense oligodeoxynucleotide phosphorothioates in drug-resistant strains. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Y. Oh,et al.  Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection , 1995, Antimicrobial agents and chemotherapy.

[16]  M. Brown,et al.  Lipoarabinomannans derived from different strains of Mycobacterium tuberculosis differentially stimulate the activation of NF-kappa B and KBF1 in murine macrophages , 1995, Infection and immunity.

[17]  J. Toulmé,et al.  Antisense phosphorothioate oligonucleotides: selective killing of the intracellular parasite Leishmania amazonensis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[18]  N. Reiner,et al.  Altered cell signaling and mononuclear phagocyte deactivation during intracellular infection. , 1994, Immunology today.

[19]  P. Das,et al.  Neoglycoprotein conjugated liposomes as macrophage specific drug carrier in the therapy of leishmaniasis. , 1994, Biochemical and biophysical research communications.

[20]  H. P. Gupta,et al.  Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice , 1994, Antimicrobial Agents and Chemotherapy.

[21]  P. Schlesinger,et al.  Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. , 1994, Science.

[22]  C. Smith,et al.  Complement and tumor necrosis factor‐α contribute to Mac‐1 (CD11b/CD18) up‐regulation and systemic neutrophil activation during endotoxemia in vivo , 1994, Journal of leukocyte biology.

[23]  L. Schlesinger Macrophage phagocytosis of virulent but not attenuated strains of Mycobacterium tuberculosis is mediated by mannose receptors in addition to complement receptors. , 1993, Journal of immunology.

[24]  A. Periasamy,et al.  Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. , 1991, Nucleic acids research.

[25]  E. Uhlmann,et al.  Antisense oligonucleotides: a new therapeutic principle , 1990 .

[26]  L. Neckers,et al.  Characterization of oligonucleotide transport into living cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[27]  K. Jayaraman,et al.  Selective inhibition of Escherichia coli protein synthesis and growth by nonionic oligonucleotides complementary to the 3' end of 16S rRNA. , 1981, Proceedings of the National Academy of Sciences of the United States of America.